01 16GlaxoSmithKline Inc.
01 22398887
02 22452217
03 32606282
04 22636436
05 22654115
06 32810524
07 23060290
01 2CABOTEGRAVIR
02 14CABOTEGRAVIR | RILPIVIRINE
01 16SUSPENSION (EXTENDED-RELEASE)
01 11931-09-15
02 22021-02-26
03 22022-08-09
04 32026-04-28
05 22027-01-19
06 22027-06-22
07 22031-01-24
08 22031-09-15
Patent Expiration Date : 2026-04-28
Date Granted : 2016-04-26
Brand Name : APRETUDE
Patent Number : 2606282
Filing Date : 2006-04-28
Strength per Unit : 200 mg / mL
Dosage Form : SUSPENSION (EXTENDED-RELEASE)
Human Or VET : Human
Route of Administration : INTRAMUSCULAR
Patent Expiration Date : 2026-04-28
Date Granted : 2016-04-26
Patent Expiration Date : 1931-09-15
Date Granted : 2018-06-26
Brand Name : APRETUDE
Patent Number : 2810524
Filing Date : 2011-09-15
Strength per Unit : 200 mg / mL
Dosage Form : SUSPENSION (EXTENDED-RELEASE)
Human Or VET : Human
Route of Administration : INTRAMUSCULAR
Patent Expiration Date : 1931-09-15
Date Granted : 2018-06-26
Patent Expiration Date : 2021-02-26
Date Granted : 2008-12-16
Brand Name : CABENUVA
Patent Number : 2398887
Filing Date : 2001-02-26
Strength per Unit : 2mL / vial kit: 200 mg / mL, 300 mg / mL
Dosage Form : SUSPENSION (EXTENDED-RELEASE)
Human Or VET : Human
Route of Administration : INTRAMUSCULAR
Patent Expiration Date : 2021-02-26
Date Granted : 2008-12-16
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Patent Expiration Date : 2022-08-09
Date Granted : 2009-06-16
Brand Name : CABENUVA
Patent Number : 2452217
Filing Date : 2002-08-09
Strength per Unit : 2mL / vial kit: 200 mg / mL, 300 mg / mL
Dosage Form : SUSPENSION (EXTENDED-RELEASE)
Human Or VET : Human
Route of Administration : INTRAMUSCULAR
Patent Expiration Date : 2022-08-09
Date Granted : 2009-06-16
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Patent Expiration Date : 2026-04-28
Date Granted : 2016-04-26
Brand Name : CABENUVA
Patent Number : 2606282
Filing Date : 2006-04-28
Strength per Unit : 2mL / vial kit: 200 mg / mL, 300 mg / mL
Dosage Form : SUSPENSION (EXTENDED-RELEASE)
Human Or VET : Human
Route of Administration : INTRAMUSCULAR
Patent Expiration Date : 2026-04-28
Date Granted : 2016-04-26
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Patent Expiration Date : 2027-01-19
Date Granted : 2014-04-01
Brand Name : CABENUVA
Patent Number : 2636436
Filing Date : 2007-01-19
Strength per Unit : 2mL / vial kit: 200 mg / mL, 300 mg / mL
Dosage Form : SUSPENSION (EXTENDED-RELEASE)
Human Or VET : Human
Route of Administration : INTRAMUSCULAR
Patent Expiration Date : 2027-01-19
Date Granted : 2014-04-01
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Patent Expiration Date : 2027-06-22
Date Granted : 2015-12-22
Brand Name : CABENUVA
Patent Number : 2654115
Filing Date : 2007-06-22
Strength per Unit : 2mL / vial kit: 200 mg / mL, 300 mg / mL
Dosage Form : SUSPENSION (EXTENDED-RELEASE)
Human Or VET : Human
Route of Administration : INTRAMUSCULAR
Patent Expiration Date : 2027-06-22
Date Granted : 2015-12-22
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Patent Expiration Date : 2031-09-15
Date Granted : 2018-06-26
Brand Name : CABENUVA
Patent Number : 2810524
Filing Date : 2011-09-15
Strength per Unit : 2mL / vial kit: 200 mg / mL, 300 mg / mL
Dosage Form : SUSPENSION (EXTENDED-RELEASE)
Human Or VET : Human
Route of Administration : INTRAMUSCULAR
Patent Expiration Date : 2031-09-15
Date Granted : 2018-06-26
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Patent Expiration Date : 2026-04-28
Date Granted : 2016-04-26
Brand Name : CABENUVA
Patent Number : 2606282
Filing Date : 2006-04-28
Strength per Unit : 3mL / vial kit: 200 mg / mL, 300 mg / mL
Dosage Form : SUSPENSION (EXTENDED-RELEASE)
Human Or VET : Human
Route of Administration : INTRAMUSCULAR
Patent Expiration Date : 2026-04-28
Date Granted : 2016-04-26
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Patent Expiration Date : 2022-08-09
Date Granted : 2009-06-16
Brand Name : CABENUVA
Patent Number : 2452217
Filing Date : 2002-08-09
Strength per Unit : 3mL / vial kit: 200 mg / mL, 300 mg / mL
Dosage Form : SUSPENSION (EXTENDED-RELEASE)
Human Or VET : Human
Route of Administration : INTRAMUSCULAR
Patent Expiration Date : 2022-08-09
Date Granted : 2009-06-16
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
